Kobayashi Pharmaceutical's Red Yeast Rice Controversy: Majority of Patients Found to Have Fanconi Syndrome, According to the Japanese Society of Nephrology
According to a report by MBS News on April 10th, the controversy surrounding Kobayashi Pharmaceutical's involvement in the "Red Yeast Rice" incident continues to escalate. The Japanese Society of Nephrology has revealed the results of their investigation on April 9th, indicating that the majority of patients who consumed Kobayashi Pharmaceutical's health products containing red yeast rice have developed Fanconi syndrome.
As of April 9th, a total of 212 consumers who took the red yeast rice-containing health products have been hospitalized, 1,224 individuals sought medical treatment, and there have been approximately 53,000 related inquiries. In order to investigate the matter, the Japanese Society of Nephrology collected samples of the problematic health products and conducted a detailed survey among 95 affected patients. The survey results showed that the majority of these patients indeed had Fanconi syndrome, a disorder affecting the function of the renal tubules. Their renal tubules exhibited abnormalities and were unable to properly reabsorb various substances required by the body, leading to the excretion of these substances.
The issue surrounding Kobayashi Pharmaceutical's health products has garnered significant attention, and the findings from the Japanese Society of Nephrology further intensify the focus on this incident. Relevant authorities are conducting a thorough investigation to determine the specific causes and implement appropriate measures. Consumers are urged to discontinue the use of these problematic health products and seek medical attention promptly if they experience related symptoms.
The progress of this matter is still under observation, and we will continue to provide the latest updates and reports.
2026-09-30
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Honeywell Acquires Johnson Matthey Catalyst Business at a Discount, Cutting £475 Million from the Price
-
$530 Million Lawsuit Unheard, $76 Million Counterclaim Filed: Is Qicai Chemical’s ‘Reputation Defense’ a Desperate Last Stand or a Calculated PR Gambit?
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
“Fake Fame” in a Forgotten Dock: Chinese Authorities Bust $100,000 Counterfeit Building Materials Ring
-
Asian Paints Dives Deeper into the Desert: Unveils Second UAE Plant to Dominate GCC Coatings Market
-
From Rust to Recharge: Novonix Ignites America’s Graphite Independence with Twin Mega-Plants in Chattanooga
-
Xampla and DIC to Introduce PFAS-Free Morro Coating to Asia
-
Brazil Slams Chinese Butyl Acrylate with Anti-Dumping Probe—Trade Tensions Heat Up in Specialty Chemicals
-
Iran Closes Strait of Hormuz to All Vessels: Global Chemical Trade Gets Choked
-
Sumitomo Reclaims Dunlop’s Throne in Southeast Asia—Full Brand Rights Snapped Up Across Malaysia, Singapore, and Brunei
Recommend Reading
-
Sichuan Unveils Revised List of 14 Qualified Chemical Parks in Major Industrial Realignment
-
IEA Warns Oil Inventories Are Draining Fast as Chemicals Enter Risk Pricing
-
One Million Tonnes of U.S. Ethane Arrive as China Sets a New Import Record
-
EU Puts Chemicals on Its China De-Risking Watchlist
-
A $25 Billion Bill Hits Global Companies as Chemical Costs Are Repriced
-
Cost Floor and Demand Constraints: Dichloromethane in Volatile Consolidation
-
Trend Slowing Down! Melamine Enters a Volatile Bottoming-Out Cycle
-
This week, the price of polyester bottle chips fluctuated and rose
-
China’s EVA Market Has Entered a Downward Trend Since May
-
This week, the Chinese urea market showed a weak downward trend (5.15-5.21)